CN116194148A - GalNAc-寡核苷酸缀合物和皂苷的治疗性组合及其用途 - Google Patents

GalNAc-寡核苷酸缀合物和皂苷的治疗性组合及其用途 Download PDF

Info

Publication number
CN116194148A
CN116194148A CN202180052532.8A CN202180052532A CN116194148A CN 116194148 A CN116194148 A CN 116194148A CN 202180052532 A CN202180052532 A CN 202180052532A CN 116194148 A CN116194148 A CN 116194148A
Authority
CN
China
Prior art keywords
saponin
xyl
rha
fuc
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180052532.8A
Other languages
English (en)
Chinese (zh)
Inventor
鲁本·波斯特尔
盖伊·赫尔曼斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Saprami Technology Co ltd
Original Assignee
Saprami Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/NL2021/050384 external-priority patent/WO2021261992A1/en
Application filed by Saprami Technology Co ltd filed Critical Saprami Technology Co ltd
Publication of CN116194148A publication Critical patent/CN116194148A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202180052532.8A 2020-06-24 2021-06-23 GalNAc-寡核苷酸缀合物和皂苷的治疗性组合及其用途 Pending CN116194148A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
NL2025902 2020-06-24
NL2025902 2020-06-24
PCT/NL2021/050384 WO2021261992A1 (en) 2020-06-24 2021-06-18 Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate
NLPCT/NL2021/050384 2021-06-18
PCT/NL2021/050394 WO2021261998A1 (en) 2020-06-24 2021-06-23 Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof

Publications (1)

Publication Number Publication Date
CN116194148A true CN116194148A (zh) 2023-05-30

Family

ID=76601666

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180052532.8A Pending CN116194148A (zh) 2020-06-24 2021-06-23 GalNAc-寡核苷酸缀合物和皂苷的治疗性组合及其用途

Country Status (9)

Country Link
US (1) US20230293562A1 (https=)
EP (2) EP4596052A3 (https=)
JP (1) JP2023533693A (https=)
KR (1) KR20230044196A (https=)
CN (1) CN116194148A (https=)
AU (1) AU2021296983A1 (https=)
CA (1) CA3183881A1 (https=)
IL (1) IL299349A (https=)
WO (1) WO2021261998A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260025101A (ko) * 2023-06-02 2026-02-23 사프렘 테크놀로지스 비.브이. 세포내 분자 표적을 통해 작용하는 치료적 이펙터 성분을 위한 개선된 치료 요법
WO2025155911A1 (en) 2024-01-18 2025-07-24 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of hurler syndrome

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011054811A1 (en) * 2009-11-03 2011-05-12 Santaris Pharma A/S Rna antagonists targeting hsp27 combination therapy
MX2016005855A (es) * 2013-11-14 2016-07-13 Roche Innovation Ct Copenhagen As Compuestos de conjugados antisentido de apolipoproteina b (apob).
SG11202106603UA (en) * 2018-12-21 2021-07-29 Sapreme Tech Bv Biologically active cluster of molecules

Also Published As

Publication number Publication date
EP4171643C0 (en) 2025-06-04
JP2023533693A (ja) 2023-08-04
US20230293562A1 (en) 2023-09-21
WO2021261998A1 (en) 2021-12-30
EP4596052A2 (en) 2025-08-06
EP4596052A3 (en) 2025-11-05
CA3183881A1 (en) 2021-12-30
KR20230044196A (ko) 2023-04-03
EP4171643B1 (en) 2025-06-04
EP4171643A1 (en) 2023-05-03
AU2021296983A1 (en) 2023-02-23
IL299349A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
AU2021295358B2 (en) Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate
EP4355369B1 (en) Conjugate of saponin, oligonucleotide and galnac
WO2022055351A1 (en) Conjugate of saponin, oligonucleotide and galnac
WO2021261992A1 (en) Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate
EP4171643B1 (en) Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof
EP4210760B1 (en) Conjugate of saponin, oligonucleotide and galnac
HK40128805A (en) Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof
AU2026202914A1 (en) Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate
HK40116734A (en) Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac oligonucleotide conjugate
CN117881427A (zh) 皂苷、寡核苷酸和galnac的缀合物
HK40124033A (en) Conjugate of saponin, oligonucleotide and galnac
HK40110483B (en) Conjugate of saponin, oligonucleotide and galnac
HK40110483A (en) Conjugate of saponin, oligonucleotide and galnac
HK40129944A (zh) Galnac和皂苷的缀合物、包含所述缀合物和galnac-寡核苷酸缀合物的治疗性组合物
HK40091234B (en) Conjugate of saponin, oligonucleotide and galnac
HK40091234A (en) Conjugate of saponin, oligonucleotide and galnac

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: Netherlands

Address after: Utrecht

Applicant after: Saprami Technology Co.,Ltd.

Address before: Holland Bilthoven

Applicant before: Saprami Technology Co.,Ltd.

Country or region before: Netherlands

CB02 Change of applicant information